Skip to main content
OpenTrials
Completed

NCT Number: NCT00271687

A Pilot Study of Exercise in Patients With Docetaxel-Based Chemotherapy for Hormone Refractory Prostate Cancer

This study aims to provide preliminary data on the feasibility and outcomes of a 12 week exercise program on the quality of life of men with hormone refractory prostate cancer receiving docetaxel-based chemotherapy.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • diagnosis of prostate cancer
  • receiving docetaxel-based chemotherapy at the CCI
  • age 18 years or over
  • approval of oncologist
  • informed written consent

Exclusion criteria

  • life expectancy less than 6 months
  • Karnofsky performance score less than 70
  • contraindications for exercise (e.g. uncontrolled cardiac, respiratory, hypertensive or psychiatric disorder)
  • unable to understand, read, write and speak English
  • unable or unwilling to attend supervised exercise sessions 3 times weekly
  • unable or unwilling to complete outcome assessments

Treatment and study plan

Exercise Training

Behavioral

Primary outcomes

  1. feasibility (recruitment, adherence, safety)

Secondary outcomes

  1. quality of life

  2. functional abilities

Sponsors and collaborators

Lead sponsor

AHS Cancer Control Alberta

Other

Collaborators

  • Cross Cancer Institute

Registry information

Important dates

Study start
2006
Primary completion
2007
Study completion
2007
First posted
Jan 4, 2006
Registry last updated
Feb 25, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.